thepeptidecatalog

Made a short breaking down exactly how BPC-157's mechanisms mirror Wolverine's healing factor. The science is wild: youtu.be/BLRHbxcdGAA (Though unlike Logan, you still need to source it legally 😉)

what to actually expect: epitalon's signal is most visible in sleep architecture, melatonin rhythm, and slow-wave time. the telomerase activation is real but glacial. anyone promising visible 'anti-aging' in 30 days is overselling the molecule. it's a long game.

the underdosing problem: people run 100mcg daily for a few weeks and quit. that is not the protocol. khavinson's work used 5-10mg per day for 10-20 days, run twice per year. course-based dosing, not chronic. sampling vs protocoling is the gap.

epitalon is the longevity peptide most people underdose. it's a 4-amino-acid pineal peptide that upregulates telomerase activity. khavinson's lab in russia ran a 12-year human study showing meaningful improvements in age-related markers across multiple cohorts.

stacks well with magnesium glycinate or apigenin for the GABAergic side, and with low-dose ipamorelin if you're already running GH peptides. don't stack with melatonin — DSIP modulates melatonin secretion endogenously, exogenous dosing fights its own mechanism.

this is why people keep saying 'i sleep 8 hours and still feel exhausted.' duration is fine, architecture is broken. DSIP at 100-200mcg SubQ before bed shifts EEG patterns toward more delta-wave activity — the restorative phase where GH pulses and tissue repair actually happen.

DSIP is the most overlooked sleep peptide. it's a 9-amino-acid neuropeptide that does not directly induce sleep — it normalizes disrupted sleep architecture. specifically restores the slow-wave deep sleep phase that gets crushed by stress, age, and cortisol dysregulation.

full breakdown — VESPER-3 numbers, what monthly dosing actually changes, and why this matters for current GLP-1 users: thepeptidecatalog.com/articles/pfize…

context for the numbers: weekly semaglutide ~15% at 68wks (STEP 1), tirzepatide ~21% at 72wks (SURMOUNT-1). PF-3944 at 28wks is in semaglutide territory at one-quarter the injection frequency. high-dose 9.6mg cohort being added to phase 3 models ~16% placebo-adjusted.

Pfizer's PF-3944 hit 12.3% placebo-adjusted weight loss at 28 weeks. one shot every four weeks. this is the molecule pfizer paid $10B for when it bought metsera in nov 2025. first credible monthly-dosed GLP-1 — and ten phase 3 trials are launching this year.

@KristieMan63702 the 28.7% number is almost hard to believe until you see the curve still trending down at week 68. mechanistically it makes sense — triple agonism (GLP-1/GIP/glucagon) is doing work the dual agonists can't. real question is the cardio safety profile in phase 3 long-term.

@peptidecatalog 28.7% at 68 weeks is wild. retatrutide can't get here fast enough tbh

the same scientists who invented GLP-1 obesity drugs just argued GLP-1 may not be needed. DiMarchi and Tschop, the team behind tirzepatide, published a paper in Molecular Metabolism showing GIP plus glucagon alone matches GLP-1 weight loss in mice and monkeys. With less nausea.

@ElevateBiohack fully agree on the goal-dependence. GHRP-2 hits harder but the cortisol/prolactin spillover is real for people sensitive to it. ipamorelin is the cleaner pulse for chronic use, GHRP-2 is the choice when you actually want appetite + GH amplitude. neither is universally better.

I think better depends on the goal, not the marketing. If you actually want stronger GH output, GHRP-2 >> ipamorelin…More robust pulses, more noticeable effect. Yes, more spillover into cortisol/prolactin, but that’s part of why it works. If you want appetite + GH (hard gainers, recovery phases), GHRP-6, People ignore it because of hunger, but mechanistically it’s one of the most reliable GHSR agonists. If you want actual optimization instead of relying on a GHRP alone, Stacking ipamorelin with CJC-1295 (no DAC / mod GRF) Now you’re working both sides GHRH + GHSR and getting real pulsatility instead of weak standalone signaling. If you want “closest to physiology”: GHRH analogs alone or properly timed pulses. You’re letting the system regulate instead of forcing it with a ghrelin mimetic. That’s the point people miss. Ipamorelin isn’t the best. It’s just the least disruptive. And sometimes the least disruptive is also the least effective. Or, you can just go GH, it’s very affordable, reliable and effective at low dose.

ipamorelin gets called the 'cleanest' GHRP and the reason is mechanistic specificity. it binds the GHSR receptor with high selectivity, triggering pulsatile GH release without spiking cortisol or prolactin like GHRP-2 and GHRP-6 do. that is the whole pitch.

full tesofensine dosing protocol, the cardio monitoring you should not skip, and how it stacks vs GLP-1s for non-responders: thepeptidecatalog.com/articles/tesof…

the catch is the side effect profile is monoaminergic — elevated heart rate, BP creep, sleep disruption at higher doses. cardiovascular safety is the reason it stalled out at FDA in 2013. Mexico approved it in 2016. that history is why most US users have never heard of it.

tesofensine is the weight loss compound nobody talks about and the data is wild. Phase 2 in obese patients hit 12.8% weight loss at 0.5mg over 24 weeks — beating semaglutide's pace head to head, with a fraction of the GI side effects. it is not a GLP-1. that is the whole point.

full GHK-Cu dosing protocol, injection vs topical, and the hair regrowth timeline most users get wrong: thepeptidecatalog.com/articles/ghk-c…

two delivery routes that actually work: subQ injection 1-2mg 3x weekly for systemic effects (hair, wound healing, fibroblast activity) or topical 0.05-0.1% formulation for skin only. oral does nothing. the peptide is destroyed in the gut.

GHK-Cu is the most underrated peptide on the market. it is a 3 amino acid sequence bound to copper that drops with age. your plasma level at 60 is roughly a third of what it was at 20. that decline tracks almost exactly with skin and tissue regeneration capacity.